MRK 241122 103.00C (MRK241122C103000) Stock Options, News & Quotes

US OptionsDetailed Quotes

MRK241122C103000

Watchlist

0.03
0.000.00%

15min DelayTrading Nov 19 11:12 ET

0.08High0.02Low

Intraday

5D
Daily

News

Merck Raises Quarterly Dividend to 81c Vs. 77c >MRK
Dow Jones23minutes ago
Express News | Merck Announces First-Quarter 2025 Dividend
Reuters23minutes ago
Tuesday Market Falls, SMCI Flies, Big Box Retail Reports Mixed | Live Stock
Kevin Travers11:11 ET
Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again. -- Barrons.com
Barron'sNov 19 10:49 ET
Merck Says Injectable Keytruda Succeeded in Late-stage Trial
Seeking AlphaNov 19 07:14 ET
Express News | Merck Shares up 1.2% Premarket After Trial Shows Injectable Version of Co's Topselling Cancer Drug Keytruda on Par With IV Form
ReutersNov 19 07:09 ET

Comments

KingThundaStorm

21 hours ago

WTF

$Merck & Co (MRK.US)$ how do drugs go up and down like this? theyre drugs, they pretty much sell themselves.

KyleyW

Nov 18 01:22

$Merck & Co (MRK.US)$ looks like he's going back to 2022

Phil Dunn

Nov 16 08:45

Portfolio change after US election

Before & after US election, I had sold out most of my stocks to reduce the risk and trim my portfolio.
Most of my stocks were closed out with profits but offset by losses in some underperforming stocks like $Centene (CNC.US)$ , $Nike (NKE.US)$ , $Merck & Co (MRK.US)$ and $Celsius Holdings (CELH.US)$ .
Both $NVIDIA (NVDA.US)$ and $Tesla (TSLA.US)$ are crucial in my portfolio for long term trading.
I had added more positions in Tesla after US election because I believe Te...

Tesla snatched biggest gain in 11 years: How long will the rally last?

101721316

Nov 15 09:38

$Merck & Co (MRK.US)$ luckily i didn"t buy in on Wednesday hoo... feel relieve

10xStockPicks

Nov 15 08:23

ESPR Will Propel Higher, Events This Weekend & Analyst Event Next Week, Stock Price

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...

+18